229 related articles for article (PubMed ID: 17822547)
1. Cost-effectiveness of activated protein C in real-life clinical practice.
Dhainaut JF; Payet S; Vallet B; França LR; Annane D; Bollaert PE; Le Tulzo Y; Runge I; Malledant Y; Guidet B; Le Lay K; Launois R;
Crit Care; 2007; 11(5):R99. PubMed ID: 17822547
[TBL] [Abstract][Full Text] [Related]
2. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator.
Yao G; Freemantle N; Calvert MJ; Bryan S; Daubert JC; Cleland JG
Eur Heart J; 2007 Jan; 28(1):42-51. PubMed ID: 17110403
[TBL] [Abstract][Full Text] [Related]
3. Systemic and organ dysfunction response during infusion of recombinant human activated protein C (rhAPC) in severe sepsis and septic shock.
Gullo A; Iscra F; Di Capua G; Berlot G; Lucangelo U; Peratoner A; Fasiolo S; Viviani M; Consales C; Zicari A
Minerva Anestesiol; 2005 Dec; 71(12):785-801. PubMed ID: 16288186
[TBL] [Abstract][Full Text] [Related]
4. Economic outcome for intensive care of infants of birthweight 500-999 g born in Victoria in the post surfactant era. The Victorian Infant Collaborative Study Group.
J Paediatr Child Health; 1997 Jun; 33(3):202-8. PubMed ID: 9259293
[TBL] [Abstract][Full Text] [Related]
5. The costs and cost-effectiveness of an integrated sepsis treatment protocol.
Talmor D; Greenberg D; Howell MD; Lisbon A; Novack V; Shapiro N
Crit Care Med; 2008 Apr; 36(4):1168-74. PubMed ID: 18379243
[TBL] [Abstract][Full Text] [Related]
6. The incremental cost effectiveness of in-patient versus out-patient rehabilitation after total hip arthroplasty - results of a pilot investigation.
Krummenauer F; Günther KP; Witzlebf WC
Eur J Med Res; 2008 Jun; 13(6):267-74. PubMed ID: 18558552
[TBL] [Abstract][Full Text] [Related]
7. Early goal-directed therapy, corticosteroid, and recombinant human activated protein C for the treatment of severe sepsis and septic shock in the emergency department.
Nguyen HB; Corbett SW; Menes K; Cho T; Daugharthy J; Klein W; Wittlake WA
Acad Emerg Med; 2006 Jan; 13(1):109-13. PubMed ID: 16365336
[TBL] [Abstract][Full Text] [Related]
8. Circumferential fusion is dominant over posterolateral fusion in a long-term perspective: cost-utility evaluation of a randomized controlled trial in severe, chronic low back pain.
Soegaard R; Bünger CE; Christiansen T; Høy K; Eiskjaer SP; Christensen FB
Spine (Phila Pa 1976); 2007 Oct; 32(22):2405-14. PubMed ID: 18090078
[TBL] [Abstract][Full Text] [Related]
9. Health system costs of out-of-hospital cardiac arrest in relation to time to shock.
van Alem AP; Dijkgraaf MG; Tijssen JG; Koster RW
Circulation; 2004 Oct; 110(14):1967-73. PubMed ID: 15381641
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of recombinant human activated protein C and the influence of severity of illness in the treatment of patients with severe sepsis.
Fowler RA; Hill-Popper M; Stasinos J; Petrou C; Sanders GD; Garber AM
J Crit Care; 2003 Sep; 18(3):181-91; discussion 191-4. PubMed ID: 14595571
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of a randomized trial comparing Helicobacter pylori test-and-treat and prompt endoscopy strategies for managing dyspepsia in a primary-care setting.
Klok RM; Arents NL; de Vries R; Thijs JC; Brouwers JR; Kleibeuker JH; Postma MJ
Clin Ther; 2005 Oct; 27(10):1647-57. PubMed ID: 16330302
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial.
Calvert MJ; Freemantle N; Yao G; Cleland JG; Billingham L; Daubert JC; Bryan S;
Eur Heart J; 2005 Dec; 26(24):2681-8. PubMed ID: 16284203
[TBL] [Abstract][Full Text] [Related]
13. Cost effectiveness of enoxaparin in acute ST-segment elevation myocardial infarction: the ExTRACT-TIMI 25 (Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction 25) study.
Marcoff L; Zhang Z; Zhang W; Ewen E; Jurkovitz C; Leguet P; Kolm P; Weintraub WS
J Am Coll Cardiol; 2009 Sep; 54(14):1271-9. PubMed ID: 19778669
[TBL] [Abstract][Full Text] [Related]
14. The COASST study: cost-effectiveness of albumin in severe sepsis and septic shock.
Guidet B; Mosqueda GJ; Priol G; Aegerter P
J Crit Care; 2007 Sep; 22(3):197-203. PubMed ID: 17869969
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of the artificial liver support system MARS in patients with acute-on-chronic liver failure.
Hessel FP; Bramlage P; Wasem J; Mitzner SR
Eur J Gastroenterol Hepatol; 2010 Feb; 22(2):213-20. PubMed ID: 19773666
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of drotrecogin alfa (activated) for the treatment of severe sepsis in the United Kingdom.
Davies A; Ridley S; Hutton J; Chinn C; Barber B; Angus DC
Anaesthesia; 2005 Feb; 60(2):155-62. PubMed ID: 15644013
[TBL] [Abstract][Full Text] [Related]
17. Activated protein C for severe sepsis.
Garces K
Issues Emerg Health Technol; 2002 Mar; (30):1-4. PubMed ID: 11985365
[TBL] [Abstract][Full Text] [Related]
18. Spinal cord stimulation versus reoperation for failed back surgery syndrome: a cost effectiveness and cost utility analysis based on a randomized, controlled trial.
North RB; Kidd D; Shipley J; Taylor RS
Neurosurgery; 2007 Aug; 61(2):361-8; discussion 368-9. PubMed ID: 17762749
[TBL] [Abstract][Full Text] [Related]
19. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.
Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of therapy with recombinant human activated protein C of critically ill surgical patients with infection complicated by septic shock and multiple organ dysfunction syndrome.
Barie PS; Hydo LJ; Shou J; Eachempati SR
Surg Infect (Larchmt); 2011 Dec; 12(6):443-9. PubMed ID: 22185191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
